

Registro Nacional de Dislipemias de la Sociedad EspaÃ±a  
actual

ClÃnica E InvestigaciÃ³n En Arteriosclerosis

29, 248-253

DOI: 10.1016/j.arteri.2017.09.001

Citation Report

#	ARTICLE	IF	CITATIONS
1	Is a national registry of dyslipidaemia necessary?. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English)</i> Tj ETQq0 0 0,rgBT /Overlock 10 T	0.1	0
2	�Es necesario un registro nacional de dislipemias?. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2017, 29, 254-255.	0.4	0
3	Hipercolesterolemia familiar en la infancia. El �xito comienza aqu�. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2018, 30, 179-180.	0.4	0
4	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1482-1492.e3.	0.6	22
5	Familial hypercholesterolaemia in childhood: Success starts here. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2018, 30, 179-180.	0.1	0
6	Criterios de derivaci�n para pacientes a las unidades de l�pidos de la Sociedad Espa�ola de Arteriosclerosis. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2019, 31, 26-30.	0.4	7
7	Criteria for referring patients to Spanish Atherosclerosis Society lipid units. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2019, 31, 26-30.	0.1	2
8	Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019, 284, 245-252.	0.4	55
9	Familial Hypercholesterolaemia Registry in the MENA Region. <i>Current Vascular Pharmacology</i> , 2019, 18, 65-67.	0.8	0
10	Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. <i>Lipids in Health and Disease</i> , 2019, 18, 216.	1.2	16
11	Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1649-1660.	0.8	13
12	Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 320, 47-52.	0.4	7
13	Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1594-1603.	1.1	9
14	Implantaci�n de un programa de cribado bioqu�mico y gen�tico de hipercolesterolemia familiar. Colaboraci�n entre el laboratorio cl�nico y las unidades de l�pidos: dise�o del Proyecto ARIAN. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2021, 33, 289-295.	0.4	2
15	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. <i>Atherosclerosis</i> , 2022, 349, 211-218.	0.4	12
16	Implantation of a biochemical and genetic screening programme for family hypercholesterolaemia. Collaboration between the clinical laboratory and lipid units: Design of the ARIAN Project. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2021, 33, 282-282.	0.1	0
18	Dyslipidemia treatment strategies in primary and secondary prevention. <i>Dyslipidemia Registry of the Spanish Arteriosclerosis Society. Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2022, , ,	0.1	0